Cefixim: clinical pharmacology and role in therapy of urogenital infections


Cite item

Full Text

Abstract

Cefixim belongs to oral cephalosporins of the third generation and has the longest half-life period among all oral cephalosporins and, therefore can be taken once a day. Moreover, cefixim presents in high concentrations in the urine, kidneys and urinary tract. In vitro, this drug has high activity against basic pathogens of urogenital infection. A randomized clinical trial has found that cefixim has higher clinical and microbiological efficacy than ciprofloxacin in patients with acute uncomplicated cystitis.

References

  1. Andes D. R., Craig W. A. Cephalosporins. In: Cohen J., Powderly W. G. et al., eds. Infectious diseases. London: Mosby; 2004. 294-307.
  2. Страчунский Л. С., Козлов С. Н. Современная антимикробная химиотерапия: Руководство для врачей. М.: Боргес; 2002.
  3. Bryskier A., Lebel M. Oral cephalosporins. In: Bryskier A. et al., eds. Antimicrobial agents: Antibacterials and antifungals. Washington: ASM Press; 2005. 222-235.
  4. Forti I. N. Review of oral cephalosporins. Basis for a rational choice. Medicina (B. Aires) 1994; 54: 439-458.
  5. Brogden R. N., Campoli-Richards D. M. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524-550.
  6. Falkowski A., Look Z., Noguchi H., Silber B. Determination of cefixime in biological samples by reversed-phase high performance liquid chromatography. J. Chromatogr. 1987; 422: 145-152.
  7. Nakashima M., Uematsu T., Takiguchi Y., Kanamaru M. Phase 1 study of cefixime, a new oral cefalosporin. J. Clin. Pharmacol. 1987; 27: 425-431.
  8. Faulkner R. D., Yocobi L. A., Barone J. S. et al. Pharmacokinetic profile of cefixime in man. Pediatr. Infect. Dis. 1987; 6: 963-970.
  9. Faulkner R. D., Fernandez P., Lawrence G. et al. Absolute bioavailability of cefixime in men. J. Clin. Pharmacol. 1988; 28: 700-706.
  10. Healy D., Sahai J., Sterling L. et al. Influence of ar/mg-containing antacids on the pharmacokinetics of cefixime. Clin. Pharmacol. Ther. 1989; 45: 164.
  11. Bialer M., Tonelli A. P., Kantrowitz J. D., Yacobi A. Serum protein binding of a new oral cephalosporin, cl 284,635, in various species. Drug Metab. Disposit.: Biol. Fate Chem. 1986; 14: 132-136.
  12. Brittain D., Scully B, Hirose T., Neu H. The pharmacokinetics and bactericidal characreristics of oral cefixime. Clin. Pharmacol. Ther. 1985; 38: 590-594.
  13. Faulkner R. D., Bohaychuk W., Desjardings R. E. et al. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J. Clin. Pharmacol. 1987; 27: 807-812.
  14. Leroy A., Oser B., Grise P., Humbert G. Cefixime penetration in human renal parenchyma. Antimicrob. Agents Chemother. 1995; 39: 1240-1242.
  15. Saito A. Pharmacokinetic studies of cefixime. Chemotherapy 1985; 33: 190-203.
  16. Guay D., Meatherall R., Harding G., Brown G. Pharmacokinetics of cefixime in healthy subjects and patients with renal insufficiency. Antimicrob. Agents Chemother. 1986; 30: 485-490.
  17. Andreu A., Alos J., Gobernado M. et al. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: A nationwide surveillance study. Enferm. Infecc. Microbiol. Clin. 2005; 1: 1-3.
  18. Hummers-Pradier E., Koch M., Ohse A. M. et al. Antibiotic resistance of urinary pathogens in female general practice patients. Scand. J. Infect. Dis. 2005; 37: 256-261.
  19. CDC: Update to cdc's sexually transmitted diseases treatment guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. Morbid. Mortal. Wkly Rep. 2007; 56: 332-336.
  20. Kubanova A., Frigo N., Kubanov A. et al. The Russian gonococcal antimicrobial susceptibility programme (ru-gasp) - national resistance prevalence in 2007 and 2008, and trends during 2005-2008. Euro Surveill. 2010; 15.
  21. ESSTI: Euro-gasp 2006 and 2007 summary report of gonorrhoeae antimicrobial susceptibility surveillance results; 2007.
  22. GISP: Gonococcal isolate surveillance project (gisp) annual report 2006. Atlanta, Georgia; 2008.
  23. Backhaus A., Tinzl J. Cefixim therapie bei patienten mit nachgewiesener gonorrhoe. Infection 1990; 18: 145-146.
  24. Kuhlwein A., Nies B. Efficacy and safety of a 400 mg single dose of oral cefixime in the treatment of uncomplicated gonorrhea. Advanc. Exp. Clin. Chemother. 1988; 1: 49-52.
  25. Hook E. W., Maccormack W. M., Martin D. et al. Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. Antimicrob. Agents Chemother. 1997; 41: 1843-1845.
  26. Tally F., Desjardins R., McCarthy E., Cartwright K. Safety profile of cefixime. Pediatr. Infect. Dis. 1987; 6: 976-980.
  27. Aronson J. K. et al. Meyler's side effects of drugs. In: The international encyclopedia of adverse drug reactions and interactions. 15-th ed. Oxford: Elsevier B. V., 2006.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies